Poliglusam Nanoparticles Activate T Cell Response in Breast Cancer Cell: an In Vivo and In Vitro Study.
Identifieur interne : 000302 ( Main/Exploration ); précédent : 000301; suivant : 000303Poliglusam Nanoparticles Activate T Cell Response in Breast Cancer Cell: an In Vivo and In Vitro Study.
Auteurs : Neda Soleimani [Iran] ; Akbar Vaseghi [Iran] ; Valentina Loconte [Italie]Source :
- Journal of fluorescence [ 1573-4994 ] ; 2019.
Descripteurs français
- KwdFr :
- Activation des lymphocytes (effets des médicaments et des substances chimiques), Animaux (MeSH), Apoptose (effets des médicaments et des substances chimiques), Cellules MCF-7 (MeSH), Chitosane (composition chimique), Chitosane (pharmacologie), Cytokines (métabolisme), Femelle (MeSH), Humains (MeSH), Lymphocytes T (effets des médicaments et des substances chimiques), Lymphocytes T (immunologie), Nanoparticules (MeSH), Rate (effets des médicaments et des substances chimiques), Rate (métabolisme), Souris (MeSH), Souris de lignée BALB C (MeSH), Transformation cellulaire néoplasique (MeSH), Tumeurs du sein (anatomopathologie).
- MESH :
- anatomopathologie : Tumeurs du sein.
- composition chimique : Chitosane.
- effets des médicaments et des substances chimiques : Activation des lymphocytes, Apoptose, Lymphocytes T, Rate.
- immunologie : Lymphocytes T.
- métabolisme : Cytokines, Rate.
- pharmacologie : Chitosane.
- Animaux, Cellules MCF-7, Femelle, Humains, Nanoparticules, Souris, Souris de lignée BALB C, Transformation cellulaire néoplasique.
English descriptors
- KwdEn :
- Animals (MeSH), Apoptosis (drug effects), Breast Neoplasms (pathology), Cell Transformation, Neoplastic (MeSH), Chitosan (chemistry), Chitosan (pharmacology), Cytokines (metabolism), Female (MeSH), Humans (MeSH), Lymphocyte Activation (drug effects), MCF-7 Cells (MeSH), Mice (MeSH), Mice, Inbred BALB C (MeSH), Nanoparticles (MeSH), Spleen (drug effects), Spleen (metabolism), T-Lymphocytes (drug effects), T-Lymphocytes (immunology).
- MESH :
- chemical , chemistry : Chitosan.
- drug effects : Apoptosis, Lymphocyte Activation, Spleen, T-Lymphocytes.
- immunology : T-Lymphocytes.
- chemical , metabolism : Cytokines, Spleen.
- pathology : Breast Neoplasms.
- chemical , pharmacology : Chitosan.
- Animals, Cell Transformation, Neoplastic, Female, Humans, MCF-7 Cells, Mice, Mice, Inbred BALB C, Nanoparticles.
Abstract
Poliglusam nanoparticles are potential therapeutic agents for the treatment of cancer. In particular, their efficacy has been reported as delivery systems in breast cancer. The aim of this study is to propose a new immunotherapeutic strategy, using Poliglusam nanoparticles as activators of the human immune response. Poliglusam nanoparticles were synthesized and characterized using both dynamic light scattering and electron microscopy. Whilst, their effectiveness in immune stimulation and detection of apoptosis was evaluated by cytokine and TUNEL assays. Finally, the cytokines pattern in splenocytes revealed an increase in IFN-γ production. The results of cytotoxicity on 4 T1 cells show an increase in the mortality rate with respect to the control cell line. The rate of apoptosis induced by Poliglusam nanoparticles on 4 T1 mouse breast cancer cell line is about 45% higher compared to MCF-7 human cells line, revealing the natural tendency of Poliglusam in increasing the production of IFN-γ in cancer cells. At the state-of-art of the knowledge, very few information have been achieved on the immunological effects of Poliglusam. This work is one of the first studies for the identification of non-functionalized Poliglusam nanoparticles impact on breast cancer. Thus, their immunotherapeutic effect, combined with an anticancer drug, can be employed as potential effective drug for eliminating breast cancer cells in the future.
DOI: 10.1007/s10895-019-02423-y
PubMed: 31493175
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Poliglusam Nanoparticles Activate T Cell Response in Breast Cancer Cell: an In Vivo and In Vitro Study.</title><author><name sortKey="Soleimani, Neda" sort="Soleimani, Neda" uniqKey="Soleimani N" first="Neda" last="Soleimani">Neda Soleimani</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran. N_soleimani@sbu.ac.ir.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Vaseghi, Akbar" sort="Vaseghi, Akbar" uniqKey="Vaseghi A" first="Akbar" last="Vaseghi">Akbar Vaseghi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nanobiotechnology, faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Nanobiotechnology, faculty of Biological Sciences, Tarbiat Modares University, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Loconte, Valentina" sort="Loconte, Valentina" uniqKey="Loconte V" first="Valentina" last="Loconte">Valentina Loconte</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, University of Padua, Padua, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical Sciences, University of Padua, Padua</wicri:regionArea><wicri:noRegion>Padua</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31493175</idno><idno type="pmid">31493175</idno><idno type="doi">10.1007/s10895-019-02423-y</idno><idno type="wicri:Area/Main/Corpus">000240</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000240</idno><idno type="wicri:Area/Main/Curation">000240</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000240</idno><idno type="wicri:Area/Main/Exploration">000240</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Poliglusam Nanoparticles Activate T Cell Response in Breast Cancer Cell: an In Vivo and In Vitro Study.</title><author><name sortKey="Soleimani, Neda" sort="Soleimani, Neda" uniqKey="Soleimani N" first="Neda" last="Soleimani">Neda Soleimani</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran. N_soleimani@sbu.ac.ir.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Vaseghi, Akbar" sort="Vaseghi, Akbar" uniqKey="Vaseghi A" first="Akbar" last="Vaseghi">Akbar Vaseghi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nanobiotechnology, faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Nanobiotechnology, faculty of Biological Sciences, Tarbiat Modares University, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Loconte, Valentina" sort="Loconte, Valentina" uniqKey="Loconte V" first="Valentina" last="Loconte">Valentina Loconte</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, University of Padua, Padua, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical Sciences, University of Padua, Padua</wicri:regionArea><wicri:noRegion>Padua</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of fluorescence</title><idno type="eISSN">1573-4994</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Apoptosis (drug effects)</term><term>Breast Neoplasms (pathology)</term><term>Cell Transformation, Neoplastic (MeSH)</term><term>Chitosan (chemistry)</term><term>Chitosan (pharmacology)</term><term>Cytokines (metabolism)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Lymphocyte Activation (drug effects)</term><term>MCF-7 Cells (MeSH)</term><term>Mice (MeSH)</term><term>Mice, Inbred BALB C (MeSH)</term><term>Nanoparticles (MeSH)</term><term>Spleen (drug effects)</term><term>Spleen (metabolism)</term><term>T-Lymphocytes (drug effects)</term><term>T-Lymphocytes (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Activation des lymphocytes (effets des médicaments et des substances chimiques)</term><term>Animaux (MeSH)</term><term>Apoptose (effets des médicaments et des substances chimiques)</term><term>Cellules MCF-7 (MeSH)</term><term>Chitosane (composition chimique)</term><term>Chitosane (pharmacologie)</term><term>Cytokines (métabolisme)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Lymphocytes T (effets des médicaments et des substances chimiques)</term><term>Lymphocytes T (immunologie)</term><term>Nanoparticules (MeSH)</term><term>Rate (effets des médicaments et des substances chimiques)</term><term>Rate (métabolisme)</term><term>Souris (MeSH)</term><term>Souris de lignée BALB C (MeSH)</term><term>Transformation cellulaire néoplasique (MeSH)</term><term>Tumeurs du sein (anatomopathologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Chitosan</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Chitosane</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term><term>Lymphocyte Activation</term><term>Spleen</term><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Activation des lymphocytes</term><term>Apoptose</term><term>Lymphocytes T</term><term>Rate</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lymphocytes T</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytokines</term><term>Spleen</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cytokines</term><term>Rate</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Chitosane</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Chitosan</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Transformation, Neoplastic</term><term>Female</term><term>Humans</term><term>MCF-7 Cells</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Nanoparticles</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules MCF-7</term><term>Femelle</term><term>Humains</term><term>Nanoparticules</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Transformation cellulaire néoplasique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Poliglusam nanoparticles are potential therapeutic agents for the treatment of cancer. In particular, their efficacy has been reported as delivery systems in breast cancer. The aim of this study is to propose a new immunotherapeutic strategy, using Poliglusam nanoparticles as activators of the human immune response. Poliglusam nanoparticles were synthesized and characterized using both dynamic light scattering and electron microscopy. Whilst, their effectiveness in immune stimulation and detection of apoptosis was evaluated by cytokine and TUNEL assays. Finally, the cytokines pattern in splenocytes revealed an increase in IFN-γ production. The results of cytotoxicity on 4 T1 cells show an increase in the mortality rate with respect to the control cell line. The rate of apoptosis induced by Poliglusam nanoparticles on 4 T1 mouse breast cancer cell line is about 45% higher compared to MCF-7 human cells line, revealing the natural tendency of Poliglusam in increasing the production of IFN-γ in cancer cells. At the state-of-art of the knowledge, very few information have been achieved on the immunological effects of Poliglusam. This work is one of the first studies for the identification of non-functionalized Poliglusam nanoparticles impact on breast cancer. Thus, their immunotherapeutic effect, combined with an anticancer drug, can be employed as potential effective drug for eliminating breast cancer cells in the future.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31493175</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-4994</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of fluorescence</Title><ISOAbbreviation>J Fluoresc</ISOAbbreviation></Journal><ArticleTitle>Poliglusam Nanoparticles Activate T Cell Response in Breast Cancer Cell: an In Vivo and In Vitro Study.</ArticleTitle><Pagination><MedlinePgn>1057-1064</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10895-019-02423-y</ELocationID><Abstract><AbstractText>Poliglusam nanoparticles are potential therapeutic agents for the treatment of cancer. In particular, their efficacy has been reported as delivery systems in breast cancer. The aim of this study is to propose a new immunotherapeutic strategy, using Poliglusam nanoparticles as activators of the human immune response. Poliglusam nanoparticles were synthesized and characterized using both dynamic light scattering and electron microscopy. Whilst, their effectiveness in immune stimulation and detection of apoptosis was evaluated by cytokine and TUNEL assays. Finally, the cytokines pattern in splenocytes revealed an increase in IFN-γ production. The results of cytotoxicity on 4 T1 cells show an increase in the mortality rate with respect to the control cell line. The rate of apoptosis induced by Poliglusam nanoparticles on 4 T1 mouse breast cancer cell line is about 45% higher compared to MCF-7 human cells line, revealing the natural tendency of Poliglusam in increasing the production of IFN-γ in cancer cells. At the state-of-art of the knowledge, very few information have been achieved on the immunological effects of Poliglusam. This work is one of the first studies for the identification of non-functionalized Poliglusam nanoparticles impact on breast cancer. Thus, their immunotherapeutic effect, combined with an anticancer drug, can be employed as potential effective drug for eliminating breast cancer cells in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soleimani</LastName><ForeName>Neda</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran. N_soleimani@sbu.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaseghi</LastName><ForeName>Akbar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nanobiotechnology, faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loconte</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Fluoresc</MedlineTA><NlmUniqueID>9201341</NlmUniqueID><ISSNLinking>1053-0509</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9012-76-4</RegistryNumber><NameOfSubstance UI="D048271">Chitosan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048271" MajorTopicYN="N">Chitosan</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">Immunotherapy and apoptosis</Keyword><Keyword MajorTopicYN="N">Nanoparticles</Keyword><Keyword MajorTopicYN="N">Poliglusam</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>03</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>07</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31493175</ArticleId><ArticleId IdType="doi">10.1007/s10895-019-02423-y</ArticleId><ArticleId IdType="pii">10.1007/s10895-019-02423-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cancer Lett. 1999 Mar 22;137(1):75-81</Citation><ArticleIdList><ArticleId IdType="pubmed">10376796</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Nanotechnol. 2007 Dec;2(12):751-60</Citation><ArticleIdList><ArticleId IdType="pubmed">18654426</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2000 Oct 15;60(20):5673-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11059759</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Res. 1994 Aug;11(8):1186-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7971722</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunopharmacol Immunotoxicol. 2012 Apr;34(2):303-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21854170</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 2005 Aug 20;116(2):304-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15800913</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Pharmacol. 2009 Jan;61(1):3-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19126291</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 1986 Jan;118(1):38-45</Citation><ArticleIdList><ArticleId IdType="pubmed">3940853</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1997 Apr 15;89(8):2635-43</Citation><ArticleIdList><ArticleId IdType="pubmed">9108380</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Treat Rev. 2000 Jun;26(3):151-68</Citation><ArticleIdList><ArticleId IdType="pubmed">10814559</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vet Med Sci. 2002 Jul;64(7):645-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12185324</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Cancer. 2007 Aug 14;7:158</Citation><ArticleIdList><ArticleId IdType="pubmed">17697357</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanomedicine. 2009 Jun;5(2):208-15</Citation><ArticleIdList><ArticleId IdType="pubmed">19186220</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2009 Feb;6(1):45-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19254479</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2007 Dec;21(14):3777-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17625071</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Nanomedicine. 2012;7:1851-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22605934</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbohydr Res. 2004 Nov 15;339(16):2693-700</Citation><ArticleIdList><ArticleId IdType="pubmed">15519328</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Proced Online. 2017 Jul 20;19:8</Citation><ArticleIdList><ArticleId IdType="pubmed">28814944</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2003 Jan 2;250(1):215-26</Citation><ArticleIdList><ArticleId IdType="pubmed">12480287</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2016 Aug;97:34-50</Citation><ArticleIdList><ArticleId IdType="pubmed">27162073</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2006 Oct 1;66(19):9339-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16990346</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 2000 Mar;82(6):1138-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10735496</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109</Citation><ArticleIdList><ArticleId IdType="pubmed">11900986</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Res. 1997 Oct;14(10):1431-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9358557</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Iran</li><li>Italie</li></country></list><tree><country name="Iran"><noRegion><name sortKey="Soleimani, Neda" sort="Soleimani, Neda" uniqKey="Soleimani N" first="Neda" last="Soleimani">Neda Soleimani</name></noRegion><name sortKey="Vaseghi, Akbar" sort="Vaseghi, Akbar" uniqKey="Vaseghi A" first="Akbar" last="Vaseghi">Akbar Vaseghi</name></country><country name="Italie"><noRegion><name sortKey="Loconte, Valentina" sort="Loconte, Valentina" uniqKey="Loconte V" first="Valentina" last="Loconte">Valentina Loconte</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000302 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000302 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= BiopestPeptidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31493175
|texte= Poliglusam Nanoparticles Activate T Cell Response in Breast Cancer Cell: an In Vivo and In Vitro Study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31493175" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a BiopestPeptidV1
| This area was generated with Dilib version V0.6.38. |  |